Anti-amyloid monoclonal antibodies for the treatment of alzheimer disease: intersocietal recommendations for their appropriate use in Switzerland

Anti-amyloid monoclonal antibodies for the treatment of alzheimer disease: intersocietal recommendations for their appropriate use in Switzerland - Swiss Memory Clinics (SMC)

The association of Swiss Memory Clinics (SMC) provides intersocietal recommendations for the use of anti-amyloid monoclonal antibodies (mAbs) in Switzerland. The recommendations are the result of extensive interdisciplinary discussions in a group of Swiss dementia experts from August 2023 until December 2024. They reflect the opinion of all societies involved in the diagnosis and treatment of dementia patients in Switzerland. Special emphasis is given to aspects that are specific to the Swiss landscape, including recommendations for infrastructural and personnel standards for institutions aiming to administer anti-amyloid mAbs in Switzerland.


Read full Guideline